Tackling a novel lethal virus: a focus on H7N9 vaccine development

References

• Gao R, Cao B, Hu Y, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013;368(20):1888–1897.
   PubMed Web of Science ®Google Scholar
• Xiang N, Li X, Ren R, et al. Assessing change in avian influenza A(H7N9) virus infections during the fourth epidemic - China, september 2015-august 2016. MMWR Morb Mortal Wkly Rep. 2016;65(49):1390–1394.
   PubMed Web of Science ®Google Scholar
• Zhou L, Ren R, Yang L, et al. Sudden increase in human infection with avian influenza A(H7N9) virus in China, September-December 2016. Western Pac Surveill Response J. 2017;8(1):1–9.
   PubMedGoogle Scholar
• WHO. Human infection with avian influenza A(H7N9) virus – China. Disease outbreak news. 2017 Apr 5. [cited 2017 Apr 17]. Available from: http://www.who.int/csr/don/05-april-2017-ah7n9-china/en/
   Google Scholar
• Zhang Q, Shi J, Deng G, et al. H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science. 2013;341(6144):410–414.
   PubMed Web of Science ®Google Scholar
• Ge E, Zhang R, Li D, et al. Estimating risks of inapparent avian exposure for human infection: avian influenza virus A (H7N9) in Zhejiang province China. Sci Rep. 2017;7:40016.
   PubMed Web of Science ®Google Scholar
• Shi J, Deng G, Liu P, et al. Isolation and characterization of H7N9 viruses from live poultry markets — implication of the source of current H7N9 infection in humans. Chin Sci Bull. 2013;58(16):1857–1863.
   Google Scholar
• Shi Y, Zhang W, Wang F, et al. Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science. 2013;342(6155):243–247.
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature. 2013;499(7459):500–503.
   PubMed Web of Science ®Google Scholar
• Belser JA, Gustin KM, Pearce MB, et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature. 2013;501(7468):556–559.
   PubMed Web of Science ®Google Scholar
• Belser JA, Creager HM, Sun X, et al. Mammalian pathogenesis and transmission of H7N9 influenza viruses from three waves, 2013-2015. J Virol. 2016;90(9):4647–4657.
   PubMed Web of Science ®Google Scholar
• Wang D, Yang L, Zhu W, et al. Two outbreak sources of influenza A (H7N9) viruses have been established in China. J Virol. 2016;90(12):5561–5573.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu Z, Liu L, et al. Adaptive amino acid substitutions enhance the virulence of a novel human H7N9 influenza virus in mice. Vet Microbiol. 2016;187:8–14.
   PubMed Web of Science ®Google Scholar
• Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness. Releve Epidemiologique Hebdomadaire. 2016;91(42):485–499.
   PubMedGoogle Scholar
• Carter DM, Bloom CE, Kirchenbaum GA, et al. Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine. Vaccine. 2015;33(1):108–116.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Isakova-Sivak I, Donina S. H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine. 2013;31(42):4702–4705.
   PubMed Web of Science ®Google Scholar
• Krammer F, Albrecht RA, Tan GS, et al. Divergent H7 immunogens offer protection from H7N9 virus challenge. J Virol. 2014;88(8):3976–3985.
   PubMed Web of Science ®Google Scholar
• Krammer F, Jul-Larsen A, Margine I, et al. An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans. Clin Vaccine Immunol. 2014;21(8):1153–1163.
   PubMed Web of Science ®Google Scholar
• Xu Q, Chen Z, Cheng X, et al. Evaluation of live attenuated H7N3 and H7N7 vaccine viruses for their receptor binding preferences, immunogenicity in ferrets and cross reactivity to the novel H7N9 virus. PLoS ONE. 2013;8(10):e76884.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Isakova-Sivak I, Rekstin A. H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic? Expert Rev Vaccines. 2014;13(1):1–4.
   PubMed Web of Science ®Google Scholar
• Goff PH, Krammer F, Hai R, et al. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J Virol. 2013;87(14):8235–8240.
   PubMed Web of Science ®Google Scholar
• Chua BY, Brown LE, Jackson DC. Considerations for the rapid deployment of vaccines against H7N9 influenza. Expert Rev Vaccines. 2014;13(11):1327–1337.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Ardito M, Terry F, et al. Low immunogenicity predicted for emerging avian-origin H7N9: implication for influenza vaccine design. Hum Vaccin Immunother. 2013;9(5):950–956.
   PubMed Web of Science ®Google Scholar
• De Groot AS, Moise L, Liu R, et al. Cross-conservation of T-cell epitopes: now even more relevant to (H7N9) influenza vaccine design. Hum Vaccin Immunother. 2014;10(2):256–262.
   PubMed Web of Science ®Google Scholar
• Hekele A, Bertholet S, Archer J, et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerg Microbes Infect. 2013;2(8):e52.
   PubMed Web of Science ®Google Scholar
• Smith GE, Flyer DC, Raghunandan R, et al. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013;31(40):4305–4313.
   PubMed Web of Science ®Google Scholar
• Liu YV, Massare MJ, Pearce MB, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine. 2015;33(18):2152–2158.
   PubMed Web of Science ®Google Scholar
• Pillet S, Racine T, Nfon C, et al. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets. Vaccine. 2015;33(46):6282–6289.
   PubMed Web of Science ®Google Scholar
• Zhang L, Lu J, Chen Y, et al. Characterization of humoral responses induced by an H7N9 influenza virus-like particle vaccine in BALB/C mice. Viruses. 2015;7(8):4369–4384.
   PubMed Web of Science ®Google Scholar
• Klausberger M, Wilde M, Palmberger D, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine. 2014;32(3):355–362.
   PubMed Web of Science ®Google Scholar
• Pushko P, Pujanauski LM, Sun X, et al. Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus. Vaccine. 2015;33(38):4975–4982.
   PubMed Web of Science ®Google Scholar
• Cao W, Liepkalns JS, Kamal RP, et al. RIG-I ligand enhances the immunogenicity of recombinant H7HA protein. Cell Immunol. 2016;304-305:55–58.
   PubMed Web of Science ®Google Scholar
• To KK, Zhang AJ, Chan AS, et al. Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection. Arch Virol. 2015;160(3):777–786.
   PubMed Web of Science ®Google Scholar
• Song L, Xiong D, Kang X, et al. An avian influenza A (H7N9) virus vaccine candidate based on the fusion protein of hemagglutinin globular head and Salmonella typhimurium flagellin. BMC Biotechnol. 2015;15:79.
   PubMed Web of Science ®Google Scholar
• Song L, Xiong D, Hu M, et al. Immunopotentiation of different adjuvants on humoral and cellular immune responses induced by HA1-2 subunit vaccines of H7N9 influenza in mice. PLoS ONE2016;11(3):e0150678.
   PubMed Web of Science ®Google Scholar
• Wodal W, Schwendinger MG, Savidis-Dacho H, et al. Immunogenicity and protective efficacy of a Vero cell culture-derived whole-virus H7N9 vaccine in mice and guinea pigs. PLoS ONE. 2015;10(2):e0113963.
   PubMed Web of Science ®Google Scholar
• Chu DH, Sakoda Y, Nishi T, et al. Potency of an inactivated influenza vaccine prepared from A/duck/Mongolia/119/2008 (H7N9) against the challenge with A/Anhui/1/2013 (H7N9). Vaccine. 2014;32(28):3473–3479.
   PubMed Web of Science ®Google Scholar
• Seo SH, Kim HS. Inactivated antigen of the H7N9 influenza virus protects mice from its lethal infection. Viral Immunol. 2016;29(4):235–243.
   PubMed Web of Science ®Google Scholar
• Wong SS, Jeevan T, Kercher L, et al. A single dose of whole inactivated H7N9 influenza vaccine confers protection from severe disease but not infection in ferrets. Vaccine. 2014;32(35):4571–4577.
   PubMed Web of Science ®Google Scholar
• Pan W, Han L, Dong Z, et al. Induction of neutralizing antibodies to influenza A virus H7N9 by inactivated whole virus in mice and nonhuman primates. Antiviral Res. 2014;107:1–5.
   PubMed Web of Science ®Google Scholar
• Chia MY, Hu AY, Tseng YF, et al. Evaluation of MDCK cell-derived influenza H7N9 vaccine candidates in ferrets. PLoS ONE. 2015;10(3):e0120793.
   PubMed Web of Science ®Google Scholar
• Wong SS, Kaplan B, Zanin M, et al. Impact of adjuvants on the immunogenicity and efficacy of split-virion H7N9 vaccine in ferrets. J Infect Dis. 2015;212(4):542–551.
   PubMed Web of Science ®Google Scholar
• Duan Y, Gu H, Chen R, et al. Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine. PLoS ONE. 2014;9(6):e99322.
   PubMed Web of Science ®Google Scholar
• Ou H, Yao H, Yao W, et al. Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice. Vaccine. 2016;34(20):2362–2370.
   PubMed Web of Science ®Google Scholar
• Wu CY, Chang CY, Ma HH, et al. Squalene-adjuvanted H7N9 virus vaccine induces robust humoral immune response against H7N9 and H7N7 viruses. Vaccine. 2014;32(35):4485–4494.
   PubMed Web of Science ®Google Scholar
• Chen Z, Baz M, Lu J, et al. Development of a high-yield live attenuated H7N9 influenza virus vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol. 2014;88(12):7016–7023.
   PubMed Web of Science ®Google Scholar
• Yang X, Zhao J, Wang C, et al. Immunization with a live attenuated H7N9 influenza vaccine protects mice against lethal challenge. PLoS ONE. 2015;10(4):e0123659.
   PubMed Web of Science ®Google Scholar
• Kong H, Zhang Q, Gu C, et al. A live attenuated vaccine prevents replication and transmission of H7N9 virus in mammals. Sci Rep. 2015;5:11233.
   PubMed Web of Science ®Google Scholar
• De Jonge J, Isakova-Sivak I, van Dijken H, et al. H7N9 live attenuated influenza vaccine is highly immunogenic, prevents virus replication, and protects against severe bronchopneumonia in ferrets. Mol Ther. 2016;24(5):991–1002.
   PubMed Web of Science ®Google Scholar
• Isakova-Sivak I, Korenkov D, Smolonogina T, et al. Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model. Virology. 2017;500:209–217.
   PubMed Web of Science ®Google Scholar
• Kreijtz JH, Wiersma LC, De Gruyter HL, et al. A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. J Infect Dis. 2015;211(5):791–800.
   PubMed Web of Science ®Google Scholar
• Li Z, Gabbard JD, Johnson S, et al. Efficacy of a parainfluenza virus 5 (PIV5)-based H7N9 vaccine in mice and guinea pigs: antibody titer towards HA was not a good indicator for protection. PLoS ONE. 2015;10(3):e0120355.
   PubMed Web of Science ®Google Scholar
• Cao W, Liepkalns JS, Hassan AO, et al. A highly immunogenic vaccine against A/H7N9 influenza virus. Vaccine. 2016;34(6):744–749.
   PubMed Web of Science ®Google Scholar
• Wongthida P, Jengarn J, Narkpuk J, et al. In vitro and in vivo attenuation of vesicular stomatitis virus (VSV) by phosphoprotein deletion. PLoS ONE. 2016;11(6):e0157287.
   PubMed Web of Science ®Google Scholar
• Liu Q, Mena I, Ma J, et al. Newcastle disease virus-vectored H7 and H5 live vaccines protect chickens from challenge with H7N9 or H5N1 avian influenza viruses. J Virol. 2015;89(14):7401–7408.
   PubMed Web of Science ®Google Scholar
• Fries LF, Smith GE, Glenn GM. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013;369(26):2564–2566.
   PubMed Web of Science ®Google Scholar
• Novavax’ H7N9 avian influenza VLP vaccine positive in Phase 1/2. Hum Vaccin Immunother. 2014;10(11):3103–3104.
   PubMed Web of Science ®Google Scholar
• Bart SA, Hohenboken M, Della Cioppa G, et al. A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med. 2014;6(234):234ra255.
   Web of Science ®Google Scholar
• Mulligan MJ, Bernstein DI, Winokur P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA. 2014;312(14):1409–1419.
   PubMed Web of Science ®Google Scholar
• Jackson LA, Campbell JD, Frey SE, et al. Effect of varying doses of a monovalent H7N9 influenza vaccine with and without AS03 and MF59 adjuvants on immune response: a randomized clinical trial. JAMA. 2015;314(3):237–246.
   PubMed Web of Science ®Google Scholar
• Madan A, Segall N, Ferguson M, et al. Immunogenicity and safety of an AS03-adjuvanted H7N9 pandemic influenza vaccine in a randomized trial in healthy adults. J Infect Dis. 2016;214(11):1717–1727.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Isakova-Sivak I, Naykhin A, et al. H7N9 live attenuated influenza vaccine in healthy adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infect Dis. 2016;16(3):303–310.
   PubMed Web of Science ®Google Scholar
• Sobhanie M, Matsuoka Y, Jegaskanda S, et al. Evaluation of the safety and immunogenicity of a candidate pandemic live attenuated influenza vaccine (pLAIV) against influenza A(H7N9). J Infect Dis. 2016;213(6):922–929.
   PubMed Web of Science ®Google Scholar
• Magini D, Giovani C, Mangiavacchi S, et al. Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge. PLoS ONE. 2016;11(8):e0161193.
   PubMed Web of Science ®Google Scholar
• Kang SM, Pushko P, Bright RA, et al. Influenza virus-like particles as pandemic vaccines. Curr Top Microbiol Immunol. 2009;333:269–289.
   PubMedGoogle Scholar
• Li X, Pushko P, Tretyakova I. Recombinant hemagglutinin and virus-like particle vaccines for H7N9 influenza virus. J Vaccines Vaccin. 2015;6(3).
   PubMedGoogle Scholar
• Pushko P, Pumpens P, Grens E. Development of virus-like particle technology from small highly symmetric to large complex virus-like particle structures. Intervirology. 2013;56(3):141–165.
   PubMed Web of Science ®Google Scholar
• Bright RA, Carter DM, Daniluk S, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007;25(19):3871–3878.
   PubMed Web of Science ®Google Scholar
• Hahn T, Courbron D, Hamer M, et al. Rapid manufacture and release of a GMP batch of avian influenza a(H7N9) virus-like particle vaccine made using recombinant baculovirus-Sf9 insect cell culture technology. Bioprocessing J. 2013;1(1):1–10.
   Google Scholar
• Hu CJ, Chien CY, Liu MT, et al. Multi-antigen avian influenza a (H7N9) virus-like particles: particulate characterizations and immunogenicity evaluation in murine and avian models. BMC Biotechnol. 2017;17(1):2.
   PubMed Web of Science ®Google Scholar
• Pushko P, Tretyakova I, Hidajat R, et al. Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens. Virology. 2017;501:176–182.
   PubMed Web of Science ®Google Scholar
• Tretyakova I, Hidajat R, Hamilton G, et al. Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein. Virology. 2016;487:163–171.
   PubMed Web of Science ®Google Scholar
• FDA Approves Flublok - New Seasonal Influenza Vaccine Made Using Novel Technology. 2013 Jan 16. [cited 2017 Fab 7]. Available from: https://www.drugs.com/newdrugs/fda-approves-flublok-new-seasonal-influenza-vaccine-made-using-novel-technology-3642.html
   Google Scholar
• FDA Approves Flublok Quadrivalent Influenza Vaccine. 2016 Oct 11. [cited 2017 Feb 7]. Available from: https://www.drugs.com/newdrugs/fda-approves-flublok-quadrivalent-influenza-vaccine-4441.html
   Google Scholar
• Buckland B, Boulanger R, Fino M, et al. Technology transfer and scale-up of the Flublok recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine. 2014;32(42):5496–5502.
   PubMed Web of Science ®Google Scholar
• Cox MM, Patriarca PA, FluBlok TJ. a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses. 2008;2(6):211–219.
   PubMed Web of Science ®Google Scholar
• Barria MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis. 2013;207(1):115–124.
   PubMed Web of Science ®Google Scholar
• Petukhova G, Naikhin A, Chirkova T, et al. Comparative studies of local antibody and cellular immune responses to influenza infection and vaccination with live attenuated reassortant influenza vaccine (LAIV) utilizing a mouse nasal-associated lymphoid tissue (NALT) separation method. Vaccine. 2009;27(19):2580–2587.
   PubMed Web of Science ®Google Scholar
• Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis. 1993;168(4):881–887.
   PubMed Web of Science ®Google Scholar
• Powell TJ, Strutt T, Reome J, et al. Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunology. 2007;178(2):1030–1038.
   PubMed Web of Science ®Google Scholar
• Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis. 2005;58(4):195–207.
   PubMed Web of Science ®Google Scholar
• Chirkova TV, Naykhin AN, Petukhova GD, et al. Memory T-cell immune response in healthy young adults vaccinated with live attenuated influenza A (H5N2) vaccine. Clin Vaccine Immunol. 2011;18(10):1710–1718.
   PubMed Web of Science ®Google Scholar
• He XS, Holmes TH, Zhang C, et al. Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006;80(23):11756–11766.
   PubMed Web of Science ®Google Scholar
• Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845–853.
   PubMed Web of Science ®Google Scholar
• Rekstin AR, Kiseleva IV, Klimov AI, et al. Interferon and other proinflamatory cytokine responses in vitro following infection with wild-type and cold-adapted reassortant influenza viruses. Vaccine. 2006;24(44–46):6581–6584.
   PubMed Web of Science ®Google Scholar
• Isakova-Sivak I, Safety RL. immunogenicity and infectivity of new live attenuated influenza vaccines. Expert Rev Vaccines. 2015;14(10):1313–1329.
   PubMed Web of Science ®Google Scholar
• Shcherbik S, Pearce N, Balish A, et al. Generation and characterization of live attenuated influenza A(H7N9) candidate vaccine virus based on Russian donor of attenuation. PLoS ONE. 2015;10(9):e0138951.
   PubMed Web of Science ®Google Scholar
• Isakova-Sivak I, Korenkov D, Rudenko L. Reassortant viruses for influenza vaccines: is it time to reconsider their genome structures? Expert Rev Vaccines. 2016;15(5):565–567.
   PubMed Web of Science ®Google Scholar
• Lambe T. Novel viral vectored vaccines for the prevention of influenza. Mol Medicine. 2012;18:1153–1160.
   PubMed Web of Science ®Google Scholar
• Chung KY, Coyle EM, Jani D, et al. ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine. 2015;33(32):3953–3962.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Isakova-Sivak I. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev Vaccines. 2015;14(3):395–412. .
   PubMed Web of Science ®Google Scholar
• Coelingh KL, Luke CJ, Jin H, et al. Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev Vaccines. 2014;13(7):855–871 .
   PubMed Web of Science ®Google Scholar
• Talaat KR, Luke CJ, Khurana S, et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis. 2014;209(12):1860–1869.
   PubMed Web of Science ®Google Scholar
• Babu TM, Levine M, Fitzgerald T, et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine. 2014;32(50):6798–6804.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Naykhin A, Donina S, et al. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Hum Vaccin Immunother. 2015;11(12):2839–2848.
   PubMed Web of Science ®Google Scholar
• Wareing MD, Watson JM, Brooks MJ, et al. Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol. 2001;65(1):171–177.
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Tyrrell DA, Oxford JS, et al. Infectivity and reactogenicity of reassortant cold-adapted influenza A/Korea/1/82 vaccines obtained from the USA and USSR. Bull World Health Organ. 1987;65(3):295–301.
   PubMed Web of Science ®Google Scholar
• Gellin BG, Qadri F. Preparing for the unpredictable: the continuing need for pandemic influenza preparedness. Vaccine. 2016;34(45):5391–5392.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global pandemic influenza action plan to increase vaccine supply. 2006. [cited 2017 Feb 8]. Available from: http://apps.who.int/iris/bitstream/10665/69388/1/WHO_ IVB_06.13_eng.pdf
   Google Scholar
• Grohmann G, Francis DP, Sokhey J, et al. Challenges and successes for the grantees and the technical advisory group of WHO’s influenza vaccine technology transfer initiative. Vaccine. 2016;34(45):5420–5424.
   PubMed Web of Science ®Google Scholar
• Rudenko L, Yeolekar L, Kiseleva I, et al. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: process challenges and success stories. Vaccine. 2016;34(45):5436–5441.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Odagiri T, Tashiro M, et al. Development of an influenza A master virus for generating high-growth reassortants for A/Anhui/1/2013(H7N9) vaccine production in qualified MDCK cells. PLoS ONE. 2016;11(7):e0160040.
   PubMed Web of Science ®Google Scholar
• Mostafa A, Kanrai P, Ziebuhr J, et al. The PB1 segment of an influenza A virus H1N1 2009pdm isolate enhances the replication efficiency of specific influenza vaccine strains in cell culture and embryonated eggs. J Gen Virol. 2016;97(3):620–631.
   PubMed Web of Science ®Google Scholar
• Ping J, Lopes TJ, Nidom CA, et al. Development of high-yield influenza A virus vaccine viruses. Nat Commun. 2015;6:8148.
   PubMed Web of Science ®Google Scholar
• Ridenour C, Johnson A, Winne E, et al. Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs. Influenza Other Respir Viruses. 2015;9(5):263–270.
   PubMed Web of Science ®Google Scholar